We often talk about the “summer slide” when the heat wipes us out, but winter is just as complicated for our community. Some of us are celebrating the drop in temperatures, while others are dreading the daily pain. It really … Continue reading → Source:…
Tweet MS-SPRINT has become abit of of an MS-SNAIL RACE with a One legged snail. Yep snails have a foot but MS_SPRINT took the drug of interest from the MS-SMART trial and gave us all hope to be dashed. MS-SPRINT was done years ago with…
In the past two years, I’ve started listening to a number of podcasts. That this coincides with my becoming more sedentary is purely coincidental. That my first was the Multiple Sclerosis Podcast is less so for obvious reasons, but today I listen to podcasts about…
Multiple sclerosis (MS) may follow two distinct biological paths that differ in how early and how quickly nerve damage develops, according to a new study. Using artificial intelligence (AI) to analyze brain MRI scans together with a blood test linked to nerve damage, researchers identified…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to privosegtor, an experimental treatment from Oculis that aims to protect the vision of people experiencing acute optic neuritis. This condition, which involves inflammation of the optic nerve, is a common and often…
Tweet How do B cell depleters work?. Some say because it depletes CD20+, T cells, but affects other T cells as well so it suggests B cells are doing a lot with the immune system. This study looks at ofatumumab and T cell numbers drop…
For many people, the arrival of a new year is a celebration of the possibilities that lie ahead. For those of us living with multiple sclerosis (MS), it’s often quieter and more internal. It’s often less about making resolutions and more about facing a reckoning.…
The balance between two immune signaling molecules — CXCL13 and BAFF — may help identify the hard-to-treat inflammation in the brain and spinal cord that’s thought to be a major driver of disability progression in multiple sclerosis (MS), a study found. The findings may help…
The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone for the country…
Tweet Yesterday I did a post on Tysabri and Tyruko and we had a few posts saying the biosimilar was not the same. Some have taken to the media to aire this view, but there have been many other me-toos been introduced to the MS…